These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16282894)

  • 1. Fas expression in lung metastasis from osteosarcoma patients.
    Gordon N; Arndt CA; Hawkins DS; Doherty DK; Inwards CY; Munsell MF; Stewart J; Koshkina NV; Kleinerman ES
    J Pediatr Hematol Oncol; 2005 Nov; 27(11):611-5. PubMed ID: 16282894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
    Koshkina N; Yang Y; Kleinerman ES
    Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic osteosarcoma.
    Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
    Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
    Gordon N; Koshkina NV; Jia SF; Khanna C; Mendoza A; Worth LL; Kleinerman ES
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4503-10. PubMed ID: 17671136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
    Gordon N; Kleinerman ES
    J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
    Gordon N; Kleinerman ES
    Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
    Huang G; Nishimoto K; Yang Y; Kleinerman ES
    Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.
    Rao-Bindal K; Rao CK; Yu L; Kleinerman ES
    Pediatr Blood Cancer; 2013 Apr; 60(4):575-9. PubMed ID: 23255321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
    Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
    Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
    Koshkina NV; Khanna C; Mendoza A; Guan H; DeLauter L; Kleinerman ES
    Mol Cancer Res; 2007 Oct; 5(10):991-9. PubMed ID: 17951400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only.
    del Prever AB; Fagioli F; Berta M; Bertoni F; Ferrari S; Mercuri M
    J Pediatr Hematol Oncol; 2005 Jan; 27(1):42-5. PubMed ID: 15654278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
    Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
    J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
    Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
    Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
    Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
    Meazza C; Cefalo G; Massimino M; Daolio P; Pastorino U; Scanagatta P; Morosi C; Podda M; Ferrari A; Terenziani M; Spreafico F; Casanova M; Parafioriti A; Collini P; Gandola L; Bastoni S; Biassoni V; Schiavello E; Chiaravalli S; Puma N; Bergamaschi L; Luksch R
    Med Oncol; 2017 Nov; 34(12):191. PubMed ID: 29094224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
    Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
    Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.